EUVIMEDEUVIMED entdecken
Open Access

Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression

Hang Guo, Yaoji Li, Chengyan Jin, Xiao Qi, Jincheng Wang, Baofeng Li, Chunguang Wang

International Journal of Molecular Medicine · 28.04.2026 · 57 (6) · 1-14

DOI: 10.3892/ijmm.2026.5839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 28.04.2026. Verfasst von Hang Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Protein Kinase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

, gilteritinib inhibited H2228/Al cell growth, induced apoptosis and reduced ALK protein levels. Co‑culture and rescue experiments suggested the mechanism involved inhibiting PD‑L1 and CD8 co‑expression, corroborated by animal experiments. Gilteritinib can overcome alectinib resistance and inhibit PD‑L1 and CD8 co‑expression in ALK‑rearranged NSCLC, providing a new therapeutic strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenProtein Kinase InhibitorsPyrazinesAnaplastic Lymphoma KinaseDrug Resistance, NeoplasmCD8 AntigensAniline CompoundsGene RearrangementHumansAnimalsCell Line, TumorMice, NudeMiceGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysApoptosis

Stichwörter der Autor:innen

PD‑L1anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancergilteritinibprogrammed death‑ligand 1; cluster of differentiation 8single‑cell transcriptome sequencing

Substanzen

B7-H1 AntigenProtein Kinase InhibitorsPyrazinesAnaplastic Lymphoma KinaseCD8 AntigensCD274 protein, humanAniline CompoundsALK protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Second Hospital Affiliated to Jilin University, Changchun, Jilin 130000, P.R. China.
  • Department of Pharmacy, Jilin Cancer Hospital, Changchun, Jilin 130000, P.R. China.

Zitieren

APA

Guo, H., Li, Y., Jin, C., Qi, X., Wang, J., Li, B., & Wang, C. (2026). Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. International Journal of Molecular Medicine, 57(6), 1-14. https://doi.org/10.3892/ijmm.2026.5839

Vancouver

Guo H, Li Y, Jin C, Qi X, Wang J, Li B, et al. Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression. International Journal of Molecular Medicine. 2026;57(6):1-14. doi:10.3892/ijmm.2026.5839

BibTeX
@article{Guo2026,
  author = {Guo, Hang and Li, Yaoji and Jin, Chengyan and Qi, Xiao and Wang, Jincheng and Li, Baofeng and Wang, Chunguang},
  title = {Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression},
  journal = {International Journal of Molecular Medicine},
  year = {2026},
  volume = {57},
  number = {6},
  pages = {1--14},
  doi = {10.3892/ijmm.2026.5839}
}
Kostenlos starten →